MCL Literature Feed

This large, real-world analysis confirms a dismal prognosis (median OS 5.4 months) for MCL patients progressing after CAR-T, establishing a benchmark for future trials in this high-risk population.

This review outlines emerging therapeutic strategies, such as bispecific antibodies and novel agents, for managing mantle cell lymphoma patients who have relapsed after CAR-T cell therapy.

This Delphi consensus provides a framework to overcome CAR-T referral barriers in MCL, emphasizing early patient identification and structured collaboration between centers to improve access and timeliness of therapy.

This large real-world study confirms brexucabtagene autoleucel's high efficacy (91% ORR, 63% 1-yr PFS) in R/R MCL, supporting its standard-of-care role and suggesting earlier use improves outcomes.

This study demonstrates the feasibility of administering brexucabtagene autoleucel in an outpatient setting for MCL, a significant shift that could improve patient convenience and reduce healthcare costs.

Real-world data on commercially insured B-cell NHL patients, including MCL, reveals a 48% relapse rate at 12 months post-CAR-T, with subsequent therapies incurring significant patient out-of-pocket costs.

This review of CAR-T for MCL highlights the critical need for structured collaboration between specialized centers and community practices to manage toxicities and ensure successful patient outcomes.

Pre-clinical CD20 CAR-T cells armed with H. pylori protein (NAP) kill rituximab-relapsed MCL cells and induce a bystander immune effect, potentially overcoming antigen-loss resistance.

Dual-targeting CD20/CD19 CAR-T cells, using an adaptive on-site manufacturing process, achieved a 100% overall response rate with a favorable safety profile in relapsed/refractory MCL.

This review outlines key clinical strategies for patient selection, toxicity management, and overcoming resistance to maximize the efficacy and safety of CAR-T therapy in relapsed/refractory MCL.

This review outlines emerging treatment strategies for relapsed/refractory MCL patients who progress after CAR-T therapy, addressing a significant and growing unmet clinical need in this setting.

This meta-analysis in TP53-mutated MCL supports targeted therapy frontline and CAR-T or transplant in relapse, but confirms poor long-term survival, highlighting the need for novel approaches.

This review outlines strategies like non-viral vectors, allogeneic products, and point-of-care manufacturing to reduce CAR-T therapy costs, potentially increasing access for relapsed/refractory MCL patients.

M2-like macrophages secrete IL-1 receptor antagonist (IL-1ra), impairing CAR-T19 function in MCL, suggesting targeting the IL-1 pathway could overcome this novel resistance mechanism.

This review outlines the evolving MCL treatment paradigm, emphasizing earlier BTKi use, established CAR-T, and emerging non-covalent BTKi and bispecifics for high-risk disease like TP53-mutated MCL.

This review contrasts European and American perspectives on integrating autologous transplant, CAR-T, and allogeneic transplant into MCL treatment, offering clinical guidance in a rapidly evolving therapeutic landscape.

This review highlights ongoing trials moving CAR-T and bispecific antibodies into earlier lines of MCL therapy, signaling a potential paradigm shift away from traditional chemoimmunotherapy.

The recent FDA approval of Lisocabtagene Maraleucel provides a new CAR-T therapy for relapsed/refractory MCL, offering high response rates but requiring careful management of severe toxicities.

Hemoadsorption with CytoSorb safely reversed severe, refractory cytokine release syndrome in post-CAR-T patients, including one with MCL, offering a potential supportive strategy for managing life-threatening toxicities.

In older relapsed/refractory MCL patients, brexucabtagene autoleucel offers superior 1-year overall survival and lower non-relapse mortality versus allogeneic transplant, though long-term outcomes are similar, guiding treatment selection.

This review summarizes favorable outcomes for CAR-T and bispecific antibodies in relapsed/refractory MCL, detailing their integration into the treatment paradigm for patients with poor prognoses post-BTKi.

This review provides a practical guide for clinicians on the approved indications and real-world application of anti-CD19 CAR-T cell therapy for mantle cell lymphoma.

This review summarizes the expanding role of T-cell directing immunotherapies, like bispecifics and CAR-T, in treating relapsed/refractory NHL, providing a framework for their application in MCL.

A new CAR-T hematotoxicity score developed for B-ALL, which replaces ferritin with bone marrow burden, highlights the need to refine existing models like CAR-HT used in MCL for disease-specific prediction.

This review outlines emerging therapeutic strategies, including non-covalent BTKis, CAR-T, and bispecifics, for managing the clinically challenging population of MCL patients relapsing after covalent BTK inhibitors.

This review summarizes how BTKi integration into frontline therapy (TRIANGLE trial) challenges the role of transplant, while CAR-T cells are established as the best option after BTKi failure.

In a real-world US analysis, relapsed/refractory MCL patients receiving CAR-T had longer treatment-free intervals and lower subsequent healthcare costs compared to standard therapies, supporting its earlier use.

Brexu-cel CAR-T therapy induced a durable 15-month complete remission in a rapidly progressing, relapsed/refractory MCL patient post-BTKi, highlighting its efficacy despite manageable rare cardiovascular toxicities.

A high-risk, TP53-mutated MCL patient achieved a durable 2-year complete remission with brexucabtagene autoleucel, but developed prolonged severe cytopenias and clonal hematopoiesis, highlighting efficacy and toxicity.

This case report illustrates the efficacy of CAR-T therapy in a relapsed/refractory MCL patient who progressed after both autologous transplant and BTK inhibitor treatment, reinforcing its clinical value.